Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study
These novel data support semaglutide 2.4 mg as an efficacious obesity treatment in adolescents with obesity and advance its application by showing associated improvements in insulin sensitivity, glycemic measures, ALT, and other cardiometabolic risk factors.
Authors
- Therese Karlsson (ORCID: https://orcid.org/0000-0002-8558-8338)
- Silva Arslanian (ORCID: https://orcid.org/0000-0002-1528-9324)
- Nina M. Harder‐Lauridsen (ORCID: https://orcid.org/0000-0002-8651-5544)
- Antje Körner (ORCID: https://orcid.org/0000-0001-6001-0356)
- Bryan Goldman
- Inge Gies (ORCID: https://orcid.org/0000-0002-8571-0858)
- Mette Skalshøi Kjær
- Daniel Weghuber
- Mazen Noureddin
- Aaron S. Kelly
Institutions
- Houston Methodist (US)
- Novo Nordisk (Denmark) (DK)
- Universität Ulm (DE)
- Paracelsus Medical University (AT)
- Novo Nordisk (United States) (US)
- Methodist Hospital (US)
- University Hospital Leipzig (DE)
- Universitair Ziekenhuis Brussel (BE)
- Children's Hospital of Pittsburgh (US)
- Child, Adolescent and Family Mental Health (CA)
- University of Minnesota Medical Center (US)
- University Hospital Ulm (DE)
- Leipzig University (DE)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-11-26
- DOI
- https://doi.org/10.2337/dc25-0824
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Eli Lilly and Company
- European Society for Paediatric Endocrinology
- Novo Nordisk
- Universität Ulm
- National Institute of Diabetes and Digestive and Kidney Diseases